Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AP26113 randomized phase 2 study in ALK-positive NSCLC after crizotinib
NL-OMON47796Phase 2Recruiting
- Sponsor
- Takeda
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of brigatinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Takeda. Primary endpoint: Confirmed objective response rate. Started Jan 2015; status: recruiting.
02
Drugs
brigatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON47796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47796.